drugset / Trial / NCT01183364

A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid Tumors

NCT01183364

Phase 1 Completed 27 enrolled Synta Pharmaceuticals Corp.
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, Phase 1, dose-escalation study to determine the recommended doses of STA-9090 (ganetespib) and docetaxel for the treatment of subjects with solid tumor malignancies. The safety and tolerability of the treatment will also be evaluated.

Timeline

Start
2010-07
Primary completion
2013-03
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule Intravenous
Subject Ganetespib Small molecule Intravenous

Indications

No indication recorded.